Our Eligibility & Screening Criteria in Zantac Cases
Why work with us? We've been around for 20 years helping law firms acquire cases. One of the things that makes Atraxia Media attractive is that we handle the marketing aspect, and we also handle the intake aspect through our internal intake department. Here are the specifics of our process:
- Pre-screening. Spending time onboarding clients that aren't a good fit for your organization is the quickest way to squander time on client intake. We understand that not every situation or individual is a good fit for you, and it's ok to decline requests from individuals who would be better served elsewhere.
- Screening each case. Atraxia Media reviews Zantac leads according to your firm's case criteria.
- Following up with people who our intake department has qualified. We also have a procedure for following up on leads to make contact as efficient as possible.
- Getting contracts signed for your law practice. The attorneys we deal with have told us that our cases generally turn out better than those of others who provide similar services.
- Connecting you with prospective Zantac contracts. We can assist your legal practice in increasing the volume of appropriate cases for your focus and budget.
- Developing case-generating marketing techniques in-house. We create a unique commercial and a savvy media strategy, then work with an internal intake department to collect leads in real-time, screen them, and sign them according to your specifications.
- Obtaining signed Zantac cases that are only for your law firm. The comprehensive intake method used by Atraxia Media ensures that you receive the most contracts for your money.
Consumers may be eligible to file a Zantac lawsuit if they:
- Took the heartburn medication Zantac or the generic version ranitidine
- Were later diagnosed with cancer linked to ranitidine usage, including:
- Bladder cancer
- Breast cancer
- Colon cancer
- Esophageal cancer
- Kidney cancer
- Liver cancer
- Ovarian cancer
- Prostate cancer
- Stomach cancer
At Atraxia Media, we are experienced in pursuing Zantac cases. As such, if you're a lawyer interested in Zantac cases, we'd be delighted to assist you. We offer a proven track record of volume, low pricing, and we focus on signing the potential claimants that meet your demands.
Zantac Facts & History
Around 590 claims are centralized as part of multidistrict litigation (MDL) in the Southern District of Florida, and thousands more are expected. The MDL was established in 2020 to help manage the growing number of claims brought on behalf of former Zantac users. Discovery is expected to end by 2021.
Several Zantac class suits against ranitidine manufacturers are also pending in federal courts. They are, however, designed for persons who have purchased ranitidine but have not gotten sick. The Plaintiffs seek refunds, medical monitoring of individuals who may now face future health risks, and punitive economic damages related to their Zantac purchases.
On April 1, 2020, the U.S. Food and Drug Administration (FDA) issued in effect a Zantac recall requesting that all name-brand and ranitidine manufacturers withdraw the drug.
ZANTAC/RANITIDINE NDMA LITIGATION, MDL NO. 2924
- The Southern District of Florida (West Palm Beach)
- U.S. District Judge Robin L. Rosenberg
- Boehringer Ingelheim Pharmaceuticals, Inc.
- GlaxoSmithKline LLC; Pfizer Inc.
- Sanofi-Aventis U.S. LLC
- Sanofi U.S. Services Inc.
- Chattem, Inc
Plaintiffs allege that Zantac, and specifically the ranitidine molecule, its active ingredient, breaks down to form an alleged carcinogen known as NDMA. In other actions, consumers seek refunds and other punitive economic damages stemming from their purchases of Zantac. Allegations against manufacturers include failing to warn, false advertising, the duty of care to test their product for NDMA, and other claims associated with the FDA's discovery of NDMA in their drugs.
- According to plaintiffs who developed cancer following the use of Zantac, Sanofi allowed the deletion of emails and other evidence, violating the preservation orders issued by the Court.
- Sanofi told investors it plans to re-introduce the brand in 2021 with the generic pharmaceutical ingredient found in Pepcid; famotidine. The announcement comes after federal regulators required the drugmaker to issue a Zantac OTC recall in 2020.
- In a complaint filed in California Superior Court for Los Angeles County, a California woman said she developed breast cancer from side effects of Zantac. She alleged that the drugmaker Sanofi failed to disclose the risk users face from carcinogenic chemicals produced by the active pharmaceutical ingredient.
- Judge Robin L. Rosenberg approved a process for the direct filing of class-action claims and pleadings directly in the MDL.
- Dozens of plaintiffs who have filed Zantac lawsuits are asking Judge Robin L. Rosenberg to return their cases where they originally brought them, the California state court.
- Plaintiffs lawyers that were appointed to leadership positions in the MDL litigation outlined the types of cancer that expert reports on general causation will support, including breast, intestinal, gastric, kidney, bladder, liver, pancreatic, lung, esophageal, and prostate cancer.
- The U.S. District Judge presiding over all federal Zantac lawsuits issued a series of rulings, granting motions to dismiss involving generic versions of the recalled heartburn drug.
- Lawsuits allege that the cancer side effects from the recalled heartburn drug appear to be an inherent byproduct of ranitidine, the active pharmaceutical ingredient in Zantac.
- A Florida man filed a complaint, indicating the side effects of the recalled heartburn drug caused him to suffer gall bladder damage and develop stomach cancer as the active ingredient in Zantac released high levels of a toxic chemical byproduct.
- Plaintiffs pushed back against an attempt by generic drug manufacturers and repackagers to dismiss ranitidine class-action lawsuits.
- A Pennsylvania man indicated in a complaint filed in Pennsylvania that, due to the side effects of Zantac, he was exposed to unacceptable levels of a toxic chemical byproduct for ten years, which directly resulted in his bladder cancer diagnosis.
- According to a lawsuit filed against makers of Zantac, years of exposure to NDMA in the recalled heartburn drug caused a Florida man to develop tonsil cancer.
- Judge Robin L. Rosenberg laid out the timelines for discovery for class-action lawsuits over the cancer risk linked to Zantac.
- The U.S. District Judge presiding over all federal Zantac lawsuits has outlined a discovery process, involving thousands of claims filed by former users who indicate Zantac caused them to develop cancer.
- In a complaint filed in the U.S. District Court for the Eastern District of Missouri, a man indicated he developed stomach cancer and esophageal cancer. These were allegedly caused by high levels of NDMA released by ranitidine.
- Lawsuits were filed over the following Zantac side effects: according to allegations raised in a wrongful death lawsuit, a Louisiana man died due to cancer caused by Zantac; more than 230 people joined a class-action lawsuit over Zantac exposure, indicating the makers of Zantac should be required to provide medical monitoring to former users
- Judge Robin L. Rosenberg established procedures for preserving the testimony of plaintiffs suffering from extreme health problems
- In a lawsuit filed over the Zantac side effects a woman from Indiana alleged that she developed uterine cancer
- Lawsuits were filed over the following Zantac side effects: bladder cancer, stomach cancer, esophageal cancer, breast cancer, leukemia, and colon cancer; a Pennsylvania man allegedly developed a fatal case of pancreatic cancer
- Judge Robin L. Rosenberg indicated that, before moving forward with bellwether trials, the Court will consider challenges to the admissibility of expert witness testimony about the link between Zantac and cancer
- In the lawsuits filed in May, plaintiffs claimed they suffered the following Zantac side effects: colon cancer, bladder cancer, and breast cancer; a wrongful death lawsuit was filed in Indiana, by the family of a woman, alleging the side effects of Zantac caused her fatal breast cancer
- Judge Robin L. Rosenberg appointed a group of 25 plaintiffs' lawyers to serve in various leadership positions during coordinated pretrial proceedings
- In lawsuits filed nationwide, the plaintiffs alleged the following Zantac side effects: bladder cancer and prostate cancer
- Judge Robin L. Rosenberg ordered parties involved in the litigation to conduct a two-stage census to provide more information about all filed and unfiled claims involving former users of Zantac who have developed cancer
- Lawsuits were filed over the following Zantac side effects: kidney cancer, bladder cancer, stomach cancer, liver cancer, and prostate cancer; a plaintiff filed a class-action lawsuit in New Jersey against almost 100 generic drug manufacturers, seeking class-action status to pursue damages for all generic metformin users
- Lawsuits were filed nationwide over the following Zantac side effects: gastric cancer, colorectal cancer, and bladder cancer
- Judge Robin L. Rosenberg appointed two small groups of attorneys to serve in leadership roles to practices and procedures teams and the initial census team
- A growing number of lawsuits were filed nationwide over the following Zantac side effects: prostate cancer, esophageal cancer, colorectal cancer, or pancreatic cancer; a widow of a West Virginia man filed a wrongful death lawsuit, indicating he developed esophageal cancer; a class-action lawsuit filed in Ohio seeks payment for medical monitoring for former Zantac users
- Zantac lawsuits were consolidated for pretrial proceedings in the Federal Court System by the U.S. Judicial Panel on Multidistrict Litigation
- Class-action lawsuit filed over Zantac in New York
- Zantac kidney cancer lawsuit filed in Pennsylvania over side effects
- Product liability lawsuit filed in Colorado against several drug manufacturers over the side effects of Zantac
- Zantac class-action lawsuit filed against CVS, Walmart, as well as manufacturers, for distributing tainted meds